Story perspectives

Ketamine Boosts Immunity, Fights Depression in Nonresponders

9/14/2025

36 4

Summary

Story summary

Ketamine restores cellular inflammatory responses in patients with treatment-resistant depression (TRD), especially in nonresponders.
It impacts key inflammation-related genes, such as IRF5 and CXCL10, enhancing innate immunity.
Nonresponders show severe viral infections linked to the restoration of inflammation genes.
Type I interferons (IFN-? and IFN-?) are vital for inhibiting viral replication and activating immune responses.
The study supports previous findings on inflammatory pathways in major depressive disorder (MDD).

1 of 1

Story summary

Ketamine restores cellular inflammatory responses in patients with treatment-resistant depression (TRD), especially in nonresponders.
It impacts key inflammation-related genes, such as IRF5 and CXCL10, enhancing innate immunity.
Nonresponders show severe viral infections linked to the restoration of inflammation genes.
Type I interferons (IFN-? and IFN-?) are vital for inhibiting viral replication and activating immune responses.
The study supports previous findings on inflammatory pathways in major depressive disorder (MDD).